This website uses cookies to improve your experience. Continue if you are OK with this.
Please read our privacy policy for more details.
Reporting to: News Editor, Editor
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the healthcare industry.
We’re looking for an enthusiastic individual interested in pursuing a career in digital journalism and content marketing who will gain crucial experience in a unique role with our industry-leading editorial team.
You’ll need some experience of reporting/digital content marketing, from writing digital editorial updates to carrying out content marketing activity, including search engine and social media publishing and marketing. Depending on your level of experience, training in the various tools and platforms is available.
You will be working in a cutting-edge digital publishing environment. We’re looking for someone who has a good grasp of digital publishing, and can generate creative ideas about how to engage with readers online.
You’ll need to be able to work independently, and be able to understand and contribute to the team’s objectives and wants to make an impact and learn a lot during your time with us. The right candidate will be able to shape the product direction and positioning with a degree of autonomy.
Other requirements:
• UK resident able to reach our London (Putney) office
• Degree educated (ideally in journalism and/or digital marketing), or currently completing a
degree course
• Available to work full or part-time during office hours
If interested, please email your CV and a covering letter to the news editor via: [email protected]
Janssen targeting innovation way beyond me-too drugs in neuroscience, says Lars Leppin
Galen — a privately owned pharmaceutical company — seeks partnerships and acquisitions to drive forward its growth ambitions and build on proud legacy
President and CEO of LEO Pharma leaves the company
Biogen’s Vumerity set to gain market share in Europe, says analyst
China's Zai Lab falls, despite positive Phase III PRIME Study of Zejula
New analysis on Mesoblast’s rexlemestrocel-L could pave way for approval
China’s 2021 NDRL listing sees price cuts of up to 95%
AstraZeneca scuppers planned $8 billion takeover of Sobi
Recursion inks second deal this week, this one with Roche
Recursion and Bayer expand fibrosis collaboration
Fennec Pharma
A specialty pharmaceutical company focused on the development of Pedmark (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients.
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.
The Pharma Letter
39 to 43 Putney High Street
Putney
London
SW15 1SP
For trial and subscription enquiries please email [email protected]
For editorial enquiries, press releases and events please email [email protected]
For all other queries please email [email protected]
Agile web development by Byte9
Back to top

source